Complement Protein C1q Ignites Arthritis Through a Newly Mapped Cell Death Cascade

Rheumatoid arthritis (RA) is a chronic autoimmune condition causing progressive joint destruction, and despite existing treatments, many patients achieve incomplete relief. Understanding the precise molecular triggers of synovial inflammation remains a high priority for developing better therapies.

This commentary in Immunity highlights findings by Huang et al. showing that the complement protein C1q—long associated with immune activation—plays a direct role in driving macrophage death and inflammation in RA joints. Specifically, C1q activates SARM1, a mitochondrial enzyme, within macrophages. SARM1 then depletes intracellular NAD+, a molecule critical for cellular energy and survival, while simultaneously producing cyclic ADP-ribose (cADPR), a second messenger that amplifies inflammatory signaling.

This biochemical cascade triggers the formation of the NLRC5/NLRP12-PANoptosome, a newly characterized multi-protein complex. The PANoptosome initiates PANoptosis—a form of programmed inflammatory cell death that integrates apoptosis, pyroptosis, and necroptosis simultaneously. The resulting wave of macrophage death releases inflammatory mediators that drive synovial tissue inflammation, worsening RA pathology.

Importantly, experimental targeting of this pathway—whether at C1q, SARM1, NAD+ depletion, or PANoptosome assembly—was shown to reduce inflammation, suggesting multiple druggable nodes within this cascade. This expands the therapeutic landscape beyond existing biologics like TNF inhibitors or JAK inhibitors.

As a commentary based solely on the abstract of the primary paper by Huang et al., full mechanistic details, model systems used, and the magnitude of anti-inflammatory effects cannot be independently verified here. Nonetheless, the identification of the C1q–SARM1–NAD+–PANoptosome axis represents a significant conceptual advance in understanding innate immune-driven joint disease.